B-cell lymphoma 2 gene promoter (BCL2 promoter) (BCL2 promoter)

The B-cell lymphoma 2 (BCL2) gene promoter is a vital regulatory DNA sequence that governs the transcription of the BCL2 protein, a primary inhibitor of apoptosis. In many malignancies, particularly B-cell lymphomas and leukemias, the BCL2 gene is overexpressed—often due to the t(14;18) translocation—leading to enhanced cell survival and resistance to chemotherapy (Wikipedia, 2024; NIH, 2022). A key feature of the BCL2 P1 promoter is a guanine-rich sequence capable of folding into secondary structures known as G-quadruplexes (G4s) (ACS, 2010; PubMed, 2009). These G4 structures serve as natural transcriptional repressors; when stabilized by specific small-molecule ligands, they prevent the binding of transcription factors and the progression of RNA polymerase (Drug Discovery Today, 2022). Targeting the BCL2 promoter DNA represents an upstream therapeutic approach to silence the BCL2 oncogene, providing an alternative or complementary strategy to direct protein inhibition by BH3 mimetics like venetoclax (ResearchGate, 2018). Experimental drugs such as CX-5461 and various G4-stabilizing ligands are being explored for their ability to modulate this promoter and induce apoptosis in cancer cells (NIH, 2021; Aptose, 2018).

Other names

BCL2 P1 promoterBCL2 G-quadruplexBCL2 G4 DNAB-cell CLL/lymphoma 2 promoter

Stabilization of G-quadruplex (G4) structures within the promoter region to sterically hinder the transcriptional machinery (e.g., RNA polymerase II and transcription factors), thereby downregulating BCL2 mRNA and protein expression.